SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 171 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2015. The put-call ratio across all filers is 0.04 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $843,406 | -56.2% | 1,406,146 | -5.1% | 0.00% | – |
Q2 2023 | $1,927,140 | -30.5% | 1,482,416 | -5.8% | 0.00% | – |
Q1 2023 | $2,771,280 | +56399.1% | 1,574,172 | +0.8% | 0.00% | -100.0% |
Q4 2022 | $4,905 | -99.9% | 1,562,309 | +1.2% | 0.00% | 0.0% |
Q3 2022 | $7,563,000 | +20.9% | 1,543,513 | +2.2% | 0.00% | 0.0% |
Q2 2022 | $6,254,000 | -28.3% | 1,510,698 | +0.6% | 0.00% | 0.0% |
Q1 2022 | $8,726,000 | -26.5% | 1,501,808 | -5.2% | 0.00% | 0.0% |
Q4 2021 | $11,880,000 | -34.6% | 1,583,989 | -21.5% | 0.00% | -50.0% |
Q3 2021 | $18,177,000 | -53.7% | 2,017,476 | -38.4% | 0.00% | -60.0% |
Q2 2021 | $39,223,000 | +9.7% | 3,276,787 | +14.8% | 0.01% | 0.0% |
Q1 2021 | $35,758,000 | +28.5% | 2,853,823 | +60.1% | 0.01% | +25.0% |
Q4 2020 | $27,818,000 | +187.0% | 1,782,635 | +81.9% | 0.00% | +100.0% |
Q3 2020 | $9,691,000 | +40.0% | 979,770 | +26.8% | 0.00% | +100.0% |
Q2 2020 | $6,923,000 | +74.5% | 772,630 | +24.0% | 0.00% | 0.0% |
Q1 2020 | $3,968,000 | +57.1% | 622,894 | +106.5% | 0.00% | – |
Q4 2019 | $2,525,000 | +157.7% | 301,633 | +178.8% | 0.00% | – |
Q3 2019 | $980,000 | -7.1% | 108,189 | +8.2% | 0.00% | – |
Q2 2019 | $1,055,000 | +13.3% | 100,023 | +2.4% | 0.00% | – |
Q1 2019 | $931,000 | -21.6% | 97,651 | -5.6% | 0.00% | – |
Q4 2018 | $1,187,000 | -33.8% | 103,436 | -2.2% | 0.00% | – |
Q3 2018 | $1,792,000 | +28.9% | 105,711 | +8.0% | 0.00% | – |
Q2 2018 | $1,390,000 | -26.1% | 97,894 | -1.0% | 0.00% | – |
Q1 2018 | $1,880,000 | +446.5% | 98,888 | +372.0% | 0.00% | – |
Q4 2017 | $344,000 | +975.0% | 20,951 | +845.9% | 0.00% | – |
Q3 2017 | $32,000 | +77.8% | 2,215 | +11.3% | 0.00% | – |
Q2 2017 | $18,000 | -70.5% | 1,990 | -83.1% | 0.00% | – |
Q1 2017 | $61,000 | +1425.0% | 11,746 | +789.8% | 0.00% | – |
Q4 2016 | $4,000 | 0.0% | 1,320 | +71.2% | 0.00% | – |
Q2 2016 | $4,000 | -33.3% | 771 | -9.7% | 0.00% | – |
Q1 2016 | $6,000 | +500.0% | 854 | +928.9% | 0.00% | – |
Q4 2015 | $1,000 | -99.9% | 83 | -99.9% | 0.00% | – |
Q1 2015 | $1,896,000 | +14.5% | 120,877 | +11.0% | 0.00% | – |
Q4 2014 | $1,656,000 | +280.7% | 108,863 | +162.2% | 0.00% | – |
Q3 2013 | $435,000 | -6.2% | 41,514 | -30.2% | 0.00% | – |
Q2 2013 | $464,000 | – | 59,442 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |